Dutch startup OncoLize secures €1.5M for treating rare, deadly tumours ‘from the inside’
With this financing, OncoLize aims to extend its preclinical success with a localised drug delivery system to treat Pancreatic and ...
Search Result for 'tumour'
No Result
Norwegian biotech company Cytovation raises €17.69M to help treat solid tumours; here’s how
Cytovation is a privately held, clinical-stage immune-oncology company focused on developing CyPep-1.
Sweden’s Texray bags €3.9M funding to improve radiation protection for medical practitioners: Here’s how
Gothenburg, Sweden-based Texray, a company specialised in radiation protection textiles, announced on Tuesday that it has secured SEK 45M (approximately ...
Exscientia Business Update for Third Quarter 2023
OXFORD, U.K.--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results ...
Germany’s RAYDIAX raises €3.5M to develop cancer therapy assistance system
Magdeburg-based RAYDIAX announced that it has raised €3.5M in a fresh round of funding to develop its computed tomography-based image ...
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ESMO 2023
— Demonstrated preclinical efficacy of LSD1 inhibitor in primary AML samples — — Initial data supporting combination potential of LSD1 ...
Meet the 22 most innovative companies from North Holland
The Chamber of Commerce's Innovation Top 100 program, which showcases the potential of small and medium-sized enterprises in the Netherlands, ...
Orakl Oncology bag €3M to propel techbio platform for accelerated cancer drug development
Orakl Oncology secures €3M to advance its techbio platform, using tumour avatars to expedite drug development and revolutionise cancer treatment.
Exscientia Details Pipeline Prioritisation Strategy
Concentrating rapidly emerging pipeline on most differentiated, highest value oncology targets, including CDK7 and LSD1 programmes Partnering or discontinuing internal ...
BenevolentAI: Interim Results for the Six Months Ended 30 June 2023
Delivering on our strategic plan Merck collaboration, lead asset enters clinic, Knowledge tools in user testing and leadership changesLONDON--(BUSINESS WIRE)--Regulatory ...